Hyperprolactinaemia has for decades been an inevitable and neglected side-effect of antipsychotic medication. The recent introduction of prolactin-sparing antipsychotic agents makes a re-examination of this problem timely. This article aims to review the literature on antipsychotic induced hyperprolactinaemia and its consequences. A literature search was made for key articles, supplemented by cross referencing. During antipsychotic treatment prolactin concentrations can rise to ten times normal levels or above and existing data indicate that a large number of female patients have amenorrhoea with or without galactorrhoea. Survey data, however, suggest that clinicians underestimate the prevalence of these conditions. Antipsychotic-induced hyperprolactinaemia should become a focus of interest in the drug treatment of psychiatric patients.
Halbreich U, Kinon BJ, Gilmore JA, Kahn LS. Elevated prolactin levels in patients with Schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology 2003;suppl 1:53-67.
Weick A, Haddad PM. Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences: Selective literature review. Br J Psychiatry 2003;182:199-204.
Rao ML, Gross G, Strebel B, Halaris A, Huber G, Braunig P, Marler M. Circadian rhythm of tryptophan, serotonin, melatonin and pituitary hormones in schizophrenia. Biol Psychiatry 1994;35:151-63.
Hamner M. The effects of atypical antipsychotics on serum prolactin levels. Ann Clin Psychiatry 2002;14:163-73.
Ragson NL, Hendrick VC, Garrick T. Endocrine and metabolic disorders. In Kaplan and Saddock's Comprehensive textbook of Psychiatry, 9th edition, pg 2303-14.
Sinha YN. Structural variants of prolactin: occurrence and physiological significance. Endocrine Rev 1995;16:354-69.
Shingo T, Gregg C, Enwere E, et al. Pregnancystimulated neurogenesis in the adult female forebrain mediated by prolactin. Science 2003;299:117-20.
Exton MS, Kruger TH, Koch M, Paulson E, Knapp W, Hartmann U, Schedlowski M. Coitus induced orgasm stimulates prolactin secretion in healthy subjects. Psychoneuro endocrinology 2001;26:287-94.
Kruger TH, Haake P, Hartmann U, Schedlowski M, Exton MS. Orgasm induced prolactin secretion: feedback control of sexual drive. Neurosci Behav Rev 2002;26:31-44.
Luciano AA. Cl inical presentat ion of Hy perprolactin aemia. J Reprod Med 1999;44:1085-90.
Mansini T, Casaneuva FF, Guist ina A. Hyperprolactinemia and Prolactinomas. Endocr Metab Clin N Am 2008;37:67-99.
Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol 2006;65:265-273.
Mancini T, Casabueva FF, Giust ina A. Hyperprolact inaemia and prolact inomas. Endocrinol Rev 2009;31:167-80.
Petty RG. Prolactin and antipsychotic medications: me chani sm of action. Schizophr Res 1999;35(Suppl):S67-73.
Mah PM, Webster J. Hyperprolactinema: etiology, diagnosis, and management. Semin Reprod Med 2002;20:365-73.
Nordstrom AL, Farde L. Plasma prolactinand central D2 receptor occupancy in antipsychotic drug treated patients. J Clin Psychopharmacol 1998;18:305-10.
Meltzer HY, Fang VS. The effect of neuroleptics on serum prolactin in schizophrenic patients. Arch Gen Psychiatry 1976;33:279-86.
Gruen PH, Sachar EJ, Langer G, Altman N, Leifer M, Frantz A, Halpern FS. Prolactin responces to neuroleptics in normal and schizophrenic subjects. Arch Gen Psychiatry 1978;35:108-16.
Kuruvilla A, Peedicayil J, Srikrishna G, et al. A study of serumprolactin levels in schizophrenia: comparison of males and females. Clin Exp Pharmacol Physiol 1992;19:603-6.
Arvanitis LA, Miller BG and Seroquel Trial 13 Study Group. Multiple fixed doses of ‘Seroquel’ (quetiapine) in patients with acute exacerbations of schizophrenia: a comparisonwith haloperidol and placebo. Biol Psychiatry 1997;42:233-46.
Crawford AM, Beasley CM, Tollefson GD. The acute and long-term effects of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophr Res 1997;26:41-54.
Green AL, Brown WA. Prolactin and neuroleptic drugs. Endocrinol Metab Clin N Am 1988;17:213–23.
Turkington RW, Prolactin secretion in patients treated with various drugs: phenothiazines, tricycl ic ant idepressants, reserpine, and methyldopa. Arch Intern Med 1972;130:349-54.
Gruender G, Wetzel H, Schloesser R. et al. Neuroendocrine response to antipsychotics: effects of drug type and gender. Biol Psychiatry 1999;45: 89-97.
Kleinberg DL, Davis JM, De Coster R, et al. Prolactin levels and adverse effects in patients treated with risperidone. J Clin Psychopharmacol 1999;19: 57-61.
David SR, Taylor CC, Kinon BJ, et al. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther 2000;22:1085-96.
Breier AF, Malhotra AK, Tung-Ping S, et al. Clozapine and r i sper idone in chronic schizophrenia: effects on symptoms, parkinsonian side effects and neuroendocrine response. Am J Psychiatry 1999;156:294-8.
Goodnick PJ, Rodriguez L, Santana O. Antipsychotics: impact on prolactin levels. Exp Opin Clin Pharmacother 2002;3:1381-91.
Brown WA, Laughren TP. Tolerance to the prolactin elevated effect of neuroleptics. Psychiatry Res 1981;5:317-22.
Igarashi Y, Higuchi T, Toyoshima R, Noguchi T, Moroji T. Tolerance to prolactin secretion in the long-term treatment with neuroleptics in schizophrenia. Adv Biochem Psychopharmacol 1985;40:95-8.
Goodnick PJ, Rodriguez L, Santana O. Antipsychotics: impact on prolactin levels. Expert Opin Pharmacother 2002;3:1381-91.
Klienberg DL, Davis JM, de Coster R, Van Baelen B, Brecher M. Prolactin levels and adverse events in patients treated with resperidone. J Clin Psychopharmacol 1999;19:57-61.
Brambilla F, Gaustalla A, Guerrini A. Prolactin secretion in chronic schizophrenia. Acta Psychiatr Scand 1976;54:275-86.
Hattori N. The frequency of macroprolactinemia in pregnant women and the heterogeneity of its etiologies. J Clin Endocrinol Metab 1996;81:586-90.
Diver MJ, Ewins DL, Worth RC, Bowles S. An unusual form of big, big (macro) prolactin in a pregnant patient. Clin Chem 2001;47:346-8.
Biller BM, Luciano A, Crosignani PG, et al. Guidelines for the diagnosis and treatment of hyperprolactinemia. J Reprod Med 1999;44:1075-84.
Aizenberg D, Zemishlany Z, Dorfman-Ertog P, et al. Sexual dysfunction in male schizophrenic patients. J Clin Psychiatry 1995;56:137-41.
Knegtering H, van der Moolen AE, Castelein S et al. What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning? Psychoneuroendocrinology 2003;28(Suppl 2):109-23.
Compton MT, Miller AH. Antipsychotic induced hyperprolactinemia and sexual dysfunction. Psychopharmacol Bull 2002;36:143-64.
Beumont PJ, Gelder MG, Friesen GH, Harris GW et al. The effects of phenothiazines on endocrine function: I. Patients with inappropriate lactation and amenorrhoea. Br J Psychiatry 1974;124:413–19.
Rosen CJ, Kessenich CR. The pathophysiology and the treatment of postmenopausal osteoporosis. An evidence-based approach to estrogens replacement therapy. Endocrinol Metab Clin North Am 1997;26:295-311.
Schlechte J, el-Khoury G, Kathol M, Walkner L. Forearm and vertebral bone mineral in treated and untreated hyperprolactinemic amenorrhea. J Clin Endocrinol Metab 1987;64;1021-26.
Hankinson SE, Willett WC, Michaud DS, Manson JE, et al. Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1999;91:629-34.
Casey DE. Side effect profiles of new antipsychotic agents. J Clin Psychiatry. 1996;57 Suppl 11:40-5.
Peverill RE. Hormone therapy and venous thromboembolism. Baillieres Best Pract Res Clin Endocrinol Metab 2003;17:149-64.
Cohen LG, Biederman J. Treatment of risperidoneinduced hyperprolactinemia with a dopamine agoni s t in chi ldren. J Chi ld Adolesc Psychopharmacol 2001;11:435-40.